Medigene AG: Academic partner presented compassionate use data on AML DC vaccine at AACR conference(PresseBox) ( Planegg, )
The results show that in four out of five AML patients, Toll-like receptor-polarized DC vaccination induced or supported specific T-cell responses. Three patients continue to be in complete remission after 21, 25 and 33 months respectively, following suboptimal primary chemotherapy. Immune responses for those patients have been presented.
A fourth, younger patient also showed specific immune responses against WT-1 during 10 months of vaccination. Due to another condition, the patient received an immunosuppressant and therefore the starting immune response was lost leading to an increase of blasts in his bone marrow. Following new induction chemotherapy, he received a bone marrow transplantation and is currently also in complete remission.
Dr. Kai Pinkernell, Senior Vice President/Chief Medical Officer (CMO) of Medigene, commented: "Maintaining the majority of the treated patients in remission over the reported time periods is very encouraging in such an aggressive disease like AML, even if these data relate to a small group of patients."
The clinical data collected at the Department of Cellular Therapy at the Oslo University Hospital, Norway, under the responsibility of Prof. Gunnar Kvalheim, was presented on a poster entitled "WT1 and PRAME mRNA transfected TLR 7/8-polarized fast DC vaccines in AML patients mount specific immune responses and impact progression free survival" by Iris Bigalke M.D.. To view the abstract of the poster please visit: http://bit.ly/2nLEi6A
The Oslo University Hospital has an agreement with Medigene for use of Medigene`s new generation DC vaccines for their ongoing academic clinical studies.
About Medigene's DC vaccines:
Medigene's most advanced platform the Company develops new generation antigen-tailored dendritic cell (DC) vaccines. Dendritic cells (DC) can take up antigens, process them and present them on their surface in a form that can induce antigen-specific T cells to mature and proliferate. In this way T cells recognize and eliminate antigen-bearing tumor cells. Dendritic cells can also induce natural killer cells (NK cells) to attack tumor cells. The team of Medigene has developed new, fast and efficient methods for generating autologous (patient-specific) mature dendritic cells which have relevant characteristics to activate both T cells and NK cells.
The dendritic cells can be loaded with various tumor antigens to treat different forms of cancer.
In April 2016, the Company announced the beginning of Phase II of Medigene's clinical Phase I/II trial of DC vaccines for acute myeloid leukemia (AML). Beforehand the independent Data and Safety Monitoring Board (DSMB) came to a positive evaluation of the safety and tolerability data obtained in Phase I part of the AML DC vaccine trial after the first six patients were treated at least four times with Medigene's DC vaccine. The DSMB thereupon recommended moving on to Phase II of the trial. The treatment of the first patient in the Phase II trial commenced in April 2016. This trial provides Medigene with clinical and safety data of active immunotherapy.
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.